Ifinatamab deruxtecan

IDeate-Lung01 study interim analysis shows ifinatamab deruxtecan (I-DXd) at 12 mg/kg has 54.8% confirmed objective response rate (ORR) in extensive-stage small cell lung cancer (SCLC), significantly higher than 8 mg/kg dose (26.1% ORR). Higher dose also shows better disease control rate and intracranial activity.

I-DXd (ifinatamab deruxtecan) showed clinically meaningful responses in pretreated extensive-stage SCLC patients, with a confirmed response rate of 26.1% at 8 mg/kg and 54.8% at 12 mg/kg. The 12 mg/kg dose was selected as optimal for further study.

Triparna Sen discusses interim analysis of IDeate-Lung01 trial, showing 12 mg/kg I-DXd dose achieved 54.8% objective response rate vs 26.1% for 8 mg/kg in extensive-stage small cell lung cancer patients. 12 mg/kg selected for further trials, though more toxicity research needed.

MSD and Daiichi Sankyo presented interim results from the Ideate-Lung01 trial at WCLC, showing the 12 mg/kg dose of ifinatamab deruxtecan (I-DXd) had a 54.8% overall response rate (ORR) in extensive-stage small cell lung cancer (SCLC) patients, with a disease control rate (DCR) of 90.5%. The higher dose also showed improved progression-free and overall survival. Safety concerns included interstitial lung disease and gastrointestinal toxicities, but no 'great surprises'. The companies have started phase 3 Ideate-Lung02 study.

Merck & Daiichi Sankyo's ifinatamab deruxtecan showed a 54.8% objective response rate in pretreated ES-SCLC patients, selected as optimal dose for ongoing trials.

Ifinatamab deruxtecan (I-DXd) showed improved efficacy in heavily pretreated extensive-stage small cell lung cancer (ES-SCLC) patients, with a 12-mg/kg dose achieving a 54.8% overall response rate (ORR) vs 26.1% for an 8-mg/kg dose. The 12-mg/kg dose also had a 90.5% disease control rate (DCR) and a median duration of response (DOR) of 4.2 months, compared to 7.9 months for the 8-mg/kg dose. Both doses were generally well-tolerated, with gastrointestinal and hematologic toxicities as the primary adverse effects.

Daiichi Sankyo and Merck's ifinatamab deruxtecan shows 54.8% objective response rate at 12 mg/kg in pretreated extensive-stage small cell lung cancer patients, leading to its selection for phase 2 and 3 trials.

Merck and Daiichi Sankyo announced interim Phase 2 trial results for lung cancer treatment ifinatamab deruxtecan (I-DXd), showing objective response rates of ~55% and ~26% at 12 mg/kg and 8 mg/kg doses, respectively. The 12 mg/kg dose led to 23 partial responses, while the 8 mg/kg dose resulted in one complete and 11 partial responses. Median overall survival was 11.8 months and 9.4 months for the respective doses. Preliminary intracranial ORRs were 50.0% and 66.7% across the two dose groups. Adverse events led to 17% and 6.5% dropouts for the respective doses. The 12 mg/kg dose is selected for the trial's expansion part, with data to be presented at the World Conference on Lung Cancer in San Diego.